Beiersdorf Aktiengesellschaft

TickerBEI.XETRA
Current Price –
Beiersdorf Aktiengesellschaft – stock chart

5-year stock timeline

2026 — Full-year results 2025 published; focus on NIVEA rebalancing and Derma expansion

Beiersdorf published its 2025 annual results in early March 2026 and set 2026 priorities: rebalancing the NIVEA portfolio, further expanding Derma, and strengthening Luxury. The Supervisory Board approved the 2025 financial statements.

Investors viewed Beiersdorf as resilient in a slowing market. Group growth slowed versus 2023 but profitability held. Market perception shifted from the rapid growth narrative of 2022–2024 toward a more nuanced view emphasizing portfolio rebalancing (NIVEA), continued Derma outperformance, and selective luxury recovery. Management framed 2026 as a year of targeted course corrections.

Group sales reached €9,852 million in 2025. Organic sales growth was 2.4%. EBIT excluding special factors came to €1,378 million with an EBIT margin of 14.0% [1][3][9].

August 3, 2026 — Half-year 2026: Derma outperformance; NIVEA turnaround plan; guidance adjusted and new buyback program announced

Beiersdorf reported H1 2026 results on August 3, 2026. The company announced an 18-month turnaround and rebalancing plan for NIVEA, adjusted full-year guidance, and approved a new share buyback program as part of capital allocation.

The market regarded Beiersdorf as addressing brand-specific weakness (NIVEA) while leaning on structurally strong Derma brands. The buyback signaled management confidence in cash generation and supported shareholder returns amid near-term sales pressure.

H1 2026 group sales reached approximately €5.0 billion. Organic group sales declined 3.5%. Consumer organic declined 4.0%. EBIT excluding special factors came to €768 million with an EBIT margin of 15.5% [13][14].

October 27, 2026 — Third quarter 2026: Derma and La Prairie acceleration; NIVEA improving vs Q2; guidance confirmed

Q3 2026 results released on October 27, 2026 showed continued Derma strength, accelerating La Prairie performance, and improving net-sales dynamics for NIVEA versus H1. The company confirmed full-year 2026 guidance.

Investors viewed the execution of the NIVEA rebalancing and the Derma growth strategy as beginning to stabilize revenue trends. Confirmation of guidance reduced short-term uncertainty.

Q3 2026 group net sales reached €2.4 billion. Q3 organic sales declined 1.3%. First nine months group net sales came to €7.3 billion with an organic decline of 2.8% [6][15].

2025 — Product innovation and launches; NIVEA CELLULAR Epicelline rollout; record Derma rollouts

Beiersdorf launched major new innovations including Epicelline® introduced to the mass market and NIVEA CELLULAR Epigenetics Rejuvenating Serum. The company continued rollouts of Derma actives (Thiamidol®, Epicelline®) across key markets.

The company emphasized innovation-led premiumization in face care and Derma science to drive higher-margin growth. Investors saw product innovation as central to restoring NIVEA momentum and sustaining Derma leadership.

Group sales reached €9,852 million in 2025. Consumer sales came to €8,176 million. Derma organic growth was reported at 11.7%. EBIT excluding special factors totaled €1,378 million. EPS was €4.25 [2][3][9][7].

2024 — Record sales peak from prior-year momentum; transition toward normalization in 2025

Beiersdorf reported record sales for FY 2023 in early 2024 and entered 2024–25 with elevated comparables. 2024 was a year of continued high sales from NIVEA and Derma which set a strong prior-year base.

After the 2023 surge, investor perception shifted to watch for sustainability of double-digit growth. Markets began to expect normalization and management prepared to defend margins while investing in innovation.

FY 2023 group sales reached €9,447 million. NIVEA sales exceeded €5.0 billion in 2023 (reported as record, approximately €5.2 billion in 2023 disclosures) with organic growth around 16.2%. These 2023 figures underpinned 2024 positioning and comparables cited in 2025 reporting [20][23][10].

2023 — Powerful double-digit growth driven by NIVEA and Derma; guidance upgrades and strong share performance

2023 marked broad-based double-digit organic growth. Beiersdorf upgraded guidance during the year in mid-2023 and published strong Q3 and nine-month results that drove upward revisions.

The company was perceived as the fastest-growing major beauty firm that year—a growth compounder story driven by NIVEA's renaissance and Derma momentum. Investor confidence pushed the share to new interim highs and above-average market returns.

Group organic sales growth reached 10.8%. Record nominal group sales were reported at approximately €9.5 billion for 2023. NIVEA nominal sales exceeded €5.0 billion in 2023 with organic growth around 16.2%. Year-end share close was reported at €135.70 [16][20][26][23].

2022 — Rebound year with double-digit organic growth from pandemic trough; management continuity established

FY 2022 results showed a strong rebound with double-digit organic growth versus 2021. Management under CEO Vincent Warnery and CFO Astrid Hermann continued to implement strategic priorities.

Market perception shifted from recovery to structural growth, with emphasis on brand revitalization (especially NIVEA) and margin management. Investors started to reward recovery trajectory.

Group sales reached €8,799 million in 2022. Organic sales growth was approximately 10.2%. 2022 was cited as an "excellent year" and foundation for subsequent growth [22][10].

2021 — Leadership changes and stabilization after pandemic disruption

In 2021 Beiersdorf reported recovery from pandemic impacts and introduced CEO Vincent Warnery and CFO Astrid Hermann. Further Executive Board appointments followed (e.g., Grita Loebsack to Executive Board effective January 1, 2022).

Investors focused on management transition and execution risk amid post-pandemic normalization. The narrative was stabilization and transformation under new leadership with emphasis on sustainability and innovation.

Group sales reached €7,627 million in 2021. Organic sales growth was approximately 9.7% [24][10].

Key risks and downside factors

Beiersdorf, a German skincare company, leads the mass and premium segments through brands like NIVEA, Eucerin, and La Prairie, spanning skincare, lip care, and wound care. It faces competition from large multinational consumer-goods and cosmetics groups—L'Oréal, Unilever, Procter & Gamble, Estée Lauder, Colgate-Palmolive, and Henkel—that compete primarily on brand strength, distribution reach, and R&D capability. Regional and niche competitors also exert pressure on growth and margins. The company navigates several material headwinds: shifts in consumer demand, volatility in raw-material and input costs, accelerating competitor innovation and pricing actions, and rising regulatory and ESG compliance costs that can reshape product formulations and limit market access.

  • Weaker consumer demand or diminished brand relevance across core markets—Europe, Latin America, Asia—could compress both volume and pricing power.
  • Volatility in raw materials, packaging, and freight costs—particularly oils, surfactants, and polymers—risks compressing gross margins when price increases cannot be transferred to consumers.
  • Intense competition and accelerating innovation from global cosmetics and FMCG groups are eroding market share across both mass and premium skincare segments.
  • Regulatory, ingredient, and ESG compliance risks can trigger reformulation costs, product restrictions, or market delays. These pressures stem from evolving cosmetic safety standards, emissions regulations, and packaging or recycling requirements [8], [3].

Competitive landscape

Beiersdorf operates as a global skincare company with established brands including NIVEA, Eucerin, and La Prairie, competing across mass-market and premium segments against firms like L'Oréal, Unilever, Procter & Gamble, Estée Lauder, and Colgate-Palmolive. The business faces material headwinds from pricing and innovation competition, execution risk around NIVEA's repositioning and premium-tier growth, input cost and foreign exchange volatility, and heightened regulatory and ESG scrutiny regarding ingredients, packaging, and advertising standards across different markets.

Private competitors

  • La Prairie Group (private brand operations)

    Independent and premium skincare brands, along with their distribution partners, that compete directly with Beiersdorf's La Prairie across luxury dermocosmetic channels in specific geographic markets.

  • Regional family-owned dermocosmetic manufacturers

    Smaller family-owned manufacturers across Europe, Latin America, and Asia produce private-label and niche dermocosmetic products. They compete primarily on price or specialized formulations against established brands like Eucerin and NIVEA within their regional markets.

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Performance Figures of Beiersdorf Aktiengesellschaft

in EUR

1M High / Low
87.36 / 79.14
52W High / Low
110.15 / 67.08
5Y High / Low
147.80 / 67.08
1M
-2.19%
3M
+0.93%
6M
+10.75%
1Y
-8.17%
3Y
-32.98%
5Y
-10.36%

Relative Performance vs Benchmarks

PeriodBeiersdorf Aktiengesellschaft vs DAX vs S&P 500 (SPY)
1M -2.19% -3.90% +2.86%
3M +0.93% +2.46% +5.33%
6M +10.75% +7.34% +12.32%
1Y -8.17% -19.28% -19.56%
3Y -32.98% -94.83% -99.66%
5Y -10.36% -69.62% -76.87%

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

PeriodP/E RatioP/S RatioP/B RatioP/CF Ratio
Current18.71.82.016.7
1Y ago14.81.22.39.6
3Y ago23.12.13.530.0
5Y ago21.21.912.312.3

Frequently Asked Questions

Where is the Beiersdorf Aktiengesellschaft stock traded?

The Beiersdorf Aktiengesellschaft stock trades under the ticker BEI.XETRA on the XETRA exchange. ISIN: DE0005200000.

What does Beiersdorf Aktiengesellschaft do?

Beiersdorf Aktiengesellschaft is a company characterized by the following investment thesis:

What are the key metrics for BEI.XETRA?

Key metrics for BEI.XETRA include valuation (P/E 18.9, P/S 1.9, P/B 2), profitability (profit margin 9.75%, ROE 10.74%), and growth (revenue –, earnings –). Market capitalization is 18.01B EUR. These metrics give an overview of the company's financial performance and valuation.

How has Beiersdorf Aktiengesellschaft's stock price performed?

Beiersdorf Aktiengesellschaft's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

How is BEI.XETRA valued?

BEI.XETRA has the following valuation metrics: P/E Ratio: 18.9, P/S Ratio: 1.9, P/B Ratio: 2. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Does BEI.XETRA pay dividends?

Yes, BEI.XETRA pays dividends with a dividend yield of 1.2%. Dividends can be an important component of the total return on an investment.

What are the key risks when investing in BEI.XETRA?

Key risks for BEI.XETRA include: Beiersdorf, a German skincare company, leads the mass and premium segments through brands like NIVEA, Eucerin, and La Prairie, spanning skincare, lip care, and wound care. It faces competition from large multinational consumer-goods and cosmetics groups—L'Oréal, Unilever, Procter & Gamble, Estée Lauder, Colgate-Palmolive, and Henkel—that compete primarily on brand strength, distribution reach, and R&D capability. Regional and niche competitors also exert pressure on growth and margins. The company navigates several material headwinds: shifts in consumer demand, volatility in raw-material and input costs, accelerating competitor innovation and pricing actions, and rising regulatory and ESG compliance costs that can reshape product formulations and limit market access.
  • Weaker consumer demand or diminished brand relevance across core markets—Europe, Latin America, Asia—could compress both volume and pricing power.
  • Volatility in raw materials, packaging, and freight costs—particularly oils, surfactants, and polymers—risks compressing gross margins when price increases cannot be transferred to consumers.
  • Intense competition and accelerating innovation from global cosmetics and FMCG groups are eroding market share across both mass and premium skincare segments.
  • Regulatory, ingredient, and ESG compliance risks can trigger reformulation costs, product restrictions, or market delays. These pressures stem from evolving cosmetic safety standards, emissions regulations, and packaging or recycling requirements [8, 3, 21].
Investors should consider these risk factors carefully before making an investment decision.

Who are the main competitors of Beiersdorf Aktiengesellschaft?

Beiersdorf Aktiengesellschaft competes with several listed peers in its sector. Beiersdorf operates as a global skincare company with established brands including NIVEA, Eucerin, and La Prairie, competing across mass-market and premium segments against firms like L'Oréal, Unilever, Procter & Gamble, Estée Lauder, and Colgate-Palmolive. The business faces material headwinds from pricing and innovation competition, execution risk around NIVEA's repositioning and premium-tier growth, input cost and foreign exchange volatility, and heightened regulatory and ESG scrutiny regarding ingredients, packaging, and advertising standards across different markets.
  • Unilever PLC (ULVR.LSE)
  • The Procter & Gamble Company (PG.NYSE)
  • The Estée Lauder Companies Inc. (EL.NYSE)
  • Colgate-Palmolive Company (CL.NYSE)
  • Henkel AG & Co. KGaA (HEN3.XETRA)
  • Kao Corporation (4452.TSE)
  • Church & Dwight Co., Inc. (CHD.NYSE)
These competitors influence pricing power, growth opportunities and relative valuation.

When does Beiersdorf Aktiengesellschaft report earnings?

Beiersdorf Aktiengesellschaft's next earnings report date is March 1, 2027.

Key Metrics

Market Capitalization
18.01B EUR
P/E Ratio
18.95
Analyst Target Price
–

Valuation Metrics

P/S Ratio
1.87
P/B Ratio
2.02

Profitability Metrics

Profit Margin
9.75%
Operating Margin
13.40%
Return on Equity
10.74%
Return on Assets
7.15%

Growth Metrics

Revenue Growth
–
Earnings Growth
–

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

YearDividendYield at paymentAvg. yield
20261.00 EUR1.35%0.88%
20251.00 EUR0.84%
20241.00 EUR0.74%
20230.70 EUR0.57%
20220.70 EUR0.74%
20210.70 EUR0.78%
20200.70 EUR0.74%
20190.70 EUR0.76%
20180.70 EUR0.76%
20170.70 EUR0.77%
20160.70 EUR0.88%
20150.70 EUR0.87%
20140.70 EUR0.99%
20130.70 EUR1.03%
20120.70 EUR1.33%

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Historical earnings performance

29.4%
Beat estimate
39.2%
Miss estimate
+23.96%
Avg surprise when beat
-32.99%
Avg surprise when miss

Reports analyzed: 51

Upcoming earnings report

March 1, 2027
Next earnings date

Analyst estimates for upcoming periods

Next year
December 31, 2027
Consensus3.99
Range3.58 – 4.35
20 analysts
Est. growth vs prior: 5.24%
Revisions: 7d ↑0 ↓0 · 30d ↑7 ↓9
Next quarter
September 30, 2024
n/a

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.

20252024202320222021
Revenue9.85B9.85B9.45B8.80B7.63B
Operating income (EBIT)1.32B1.29B1.10B1.22B980.00M
Net income939.00M912.00M736.00M755.00M638.00M
Free cash flow373.00M794.00M424.00M249.00M580.00M
Total assets12.85B13.01B12.63B12.35B11.30B
Equity8.60B8.47B8.32B7.79B6.87B
Net debt-983.00M-941.00M-1.03B-722.00M-757.00M
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon